Search results for "kidney failure"

showing 10 items of 112 documents

Down with the erythropoietin. Long live the erythropoietin!

2009

In recent years the use of erythropoietin has exploded, and the anaemia of patients with chronic renal failure has been practically resolved with the administration of rHuEpo (recombinant human, Erythropoietin). However, as a result of an intense commercial campaign, strong therapies with this growth hormone, prescribed to achieve surprising sporting performances, got athletes to run the risk of thrombosis and vascular accidents because of red blood cells increase. Erythropoietin represents a significant subject of research. In fact, besides the ability of stimulating erythrocyte production, it has many pleiotropic effects. Several studies allow the assertion that EPO, in different concentr…

Settore MED/09 - Medicina InternaAngiogenesisClinical BiochemistryCentral nervous systemUrodelaStimulationAthletic PerformanceBioinformaticsRegenerative MedicineRegenerative medicineDose-Response RelationshipKidney FailureDrug DiscoverymedicineErythropoietin NeuroprotectionAnimalsHumansChronicErythropoietinPharmacologyRecombinantDose-Response Relationship Drugbusiness.industrySettore MED/27 - NeurochirurgiaRegeneration (biology)CancerAnemiamedicine.diseaseRecombinant Proteinsmedicine.anatomical_structureAnemia Angiogenesis Inducing Agents Animals Athletic Performance Dose-Response Relationship; Drug Erythropoietin Erythropoietin; Recombinant Humans Kidney Failure; Chronic Regenerative Medicine UrodelaErythropoietinImmunologyMolecular MedicineKidney Failure ChronicAngiogenesis Inducing AgentsDrugbusinessmedicine.drugHormone
researchProduct

Two Patients With History of STEC-HUS, Posttransplant Recurrence and Complement Gene Mutations

2013

Hemolytic uremic syndrome (HUS) is a disease of microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. About 90% of cases are secondary to infections by Escherichia coli strains producing Shiga-like toxins (STEC-HUS), while 10% are associated with mutations in genes encoding proteins of complement system (aHUS). We describe two patients with a clinical history of STEC-HUS, who developed end-stage renal disease (ESRD) soon after disease onset. They received a kidney transplant but lost the graft for HUS recurrence, a complication more commonly observed in aHUS. Before planning a second renal transplantation, the two patients underwent genetic screening for aHUS-associat…

Shiga-toxinGraft RejectionMaleDNA Primer030232 urology & nephrologyEscherichia coli InfectionGene mutationurologic and male genital diseasesGastroenterology0302 clinical medicineRecurrenceRisk Factorshemic and lymphatic diseasesImmunology and AllergyPharmacology (medical)gene mutationKidney transplantationEscherichia coli Infections0303 health sciencesKidneymedicine.diagnostic_testShiga-Toxigenic Escherichia coliAntigens CD46Microangiopathic hemolytic anemiaMiddle AgedPrognosisfemale genital diseases and pregnancy complications3. Good healthPedigreemedicine.anatomical_structureComplement Factor IComplement factor I; gene mutation; hemolytic uremic syndrome; kidney transplantation; membrane cofactor protein; Shiga-toxin; Adult; Antigens CD46; Case-Control Studies; Complement Factor I; DNA Primers; Escherichia coli Infections; Female; Genetic Testing; Graft Rejection; Hemolytic-Uremic Syndrome; Heterozygote; Humans; Kidney Failure Chronic; Kidney Transplantation; Male; Middle Aged; Mutation; Pedigree; Prognosis; Recurrence; Risk Factors; Shiga-Toxigenic Escherichia coli; Thrombocytopenia; Young Adult; Transplantation; Immunology and Allergy; Pharmacology (medical)FemaleCase-Control StudieHumanAdultmedicine.medical_specialtyHeterozygotePrognosiComplement factor IMembrane Cofactor Protein03 medical and health sciencesYoung AdultInternal medicinemedicineHumansGenetic Testing030304 developmental biologyGenetic testingDNA PrimersTransplantationbusiness.industryCD46Risk Factormedicine.diseaseKidney TransplantationThrombocytopeniaTransplantationCase-Control StudiesImmunologyHemolytic-Uremic SyndromeMutationhemolytic uremic syndromeKidney Failure ChronicbusinessAmerican Journal of Transplantation
researchProduct

[The role of the anesthesiologist in secondary hyperparathyroidism].

2010

In the last years the increasing of diabetes and hypertension has produced a considerable increase of patients with chronic renal failure; secondary hyperparathyroidism is one of the major complications. The resection of hyperfunctioning parathyroid tissue is the ultimate goal of the treatment. The preoperative examination by the anesthetist is the starting-point of the treatment. The anesthetist programs hemodialysis, the correction of fluid and electrolyte abnormalities and of the anaemia. In the operating room the anesthetist is involved in the careful monitoring of liquid infusion and anesthesiological procedure. The intraoperative parathyroid hormone (PTH) assay is an essential tool be…

Treatment OutcomeAnesthesiologyParathyroid HormoneRenal DialysisMonitoring IntraoperativeSettore MED/41 - AnestesiologiaHumansKidney Failure ChronicHyperparathyroidism Secondaryhyperparathyroidism calciumPhysician's RoleBiomarkersIl Giornale di chirurgia
researchProduct

Hepatitis B vaccination and interleukin 2 receptor expression in chronic renal failure

1990

Hepatitis B vaccination and interleukin-2 receptor expression in chronic renal failure. Only 50 to 60% of dialysis patients develop anti-HBs antibodies following hepatitis b vaccination. The nonre-sponder state correlates with impaired monocyte function, decreased interleukin-2 (IL-2) production of T cells, and an upregulation of the IL-2 receptor system. In the present study we examined anti-HBs production after hepatitis B vaccination and the in vitro expression of IL-2 receptors in nondialyzed patients with various degrees of chronic renal failure. Forty-four patients with impaired renal function were immunized with 20 µg recombinant hepatitis B vaccine and boostered after one and six mo…

Viral Hepatitis VaccinesT-LymphocytesReceptor expressionmedicine.disease_causechemistry.chemical_compoundmedicineHumansHepatitis B VaccinesProspective StudiesHepatitis B AntibodiesSeroconversionHepatitis B virusVaccines SyntheticCreatininebiologybusiness.industryVaccinationAntibody titerReceptors Interleukin-2Middle AgedHepatitis Bbiology.organism_classificationVaccinationchemistryHepadnaviridaeNephrologyAntibody FormationImmunologybiology.proteinKidney Failure ChronicAntibodybusinessKidney International
researchProduct

A randomized multicenter trial on a lung ultrasound-guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk

2021

Lung congestion is a risk factor for all-cause and cardiovascular mortality in patients on chronic hemodialysis, and its estimation by ultrasound may be useful to guide ultrafiltration and drug therapy in this population. In an international, multi-center randomized controlled trial (NCT02310061) we investigated whether a lung ultrasound-guided treatment strategy improved a composite end point (all-cause death, non-fatal myocardial infarction, decompensated heart failure) vs usual care in patients receiving chronic hemodialysis with high cardiovascular risk. Patient-Reported Outcomes (Depression and the Standard Form 36 Quality of Life Questionnaire, SF36) were assessed as secondary outcome…

cardiovascular riskmedicine.medical_specialtymedicine.medical_treatmentPopulationlung congestionlaw.inventionKidney FailureRandomized controlled trialRenal DialysisRisk FactorslawMulticenter trialInternal medicineHumansMedicineChronicRisk factorESRDeducationLungUltrasonography InterventionalDialysisUltrasonographylung ultrasoundeducation.field_of_studyInterventionalbusiness.industryHazard ratiochronic kidney failuremedicine.diseaseESRD; cardiovascular risk; chronic kidney failure; heart failure hemodialysis; lung congestion; lung ultrasoundHeart Disease Risk FactorsCardiovascular DiseasesNephrologyHeart failureQuality of LifeKidney Failure ChronicHemodialysisheart failure hemodialysisbusinessKidney international
researchProduct

Adiponectin plasma levels aand chronic kidney disease stages in hypertensive and normotensive subjects

2009

hypertensionadiponectinkidney failure
researchProduct

Epidemiology and pathophysiology of left ventricular abnormalities in chronic kidney disease: a review.

2010

Introduction Cardiovascular diseases are highly prevalent in patients with chronic kidney disease (CKD), and represent the major hazard for mortality in this population. Anomalies of left ventricular (LV) structure and function are very frequent too among CKD patients, and show a negative impact on cardiovascular prognosis. Methods We searched PubMed for manuscripts regarding left ventricular hypertrophy (LVH) in CKD. Definition of LVH was different according to different studies. Results In patients with end-stage renal disease, the prevalence of LVH is higher than 70%. Studies in patients with less advanced CKD have reported increasing prevalence of LVH along with declining renal function…

medicine.medical_specialtyAnemiaPopulationDiastoleRenal functionDiseaseurologic and male genital diseasesLeft ventricular hypertrophyKidneyRisk AssessmentVentricular Function LeftVentricular Dysfunction LeftRisk FactorsInternal medicinemedicinePrevalenceHumanscardiovascular diseasesIntensive care medicineeducationeducation.field_of_studyLeft ventricular dysfunctionbusiness.industryLeft ventricular hypertrophymedicine.diseaseChronic kidney disease.NephrologyHeart failureChronic DiseaseCardiologyDisease ProgressionKidney Failure ChronicHypertrophy Left VentricularKidney DiseasesbusinessKidney diseaseGlomerular Filtration RateJournal of nephrology
researchProduct

Stretching the boundaries for liver transplant in the 21st century.

2018

Given the high waiting list mortality, there is a clear need to identify strategies to increase the number of livers for transplantation. Some strategies require policy changes, whereas others depend on a better understanding of available opportunities. We divided the strategies to increase the number of livers for transplantation into two categories-those aiming to increase the use of organs considered to be of suboptimal quality, and those aiming to increase the use of organs considered to be of suboptimal size. Enough evidence suggests that, if considered in the context of other donor and recipient variables, grafts from elderly donors are a safe option. The severity of steatosis, and no…

medicine.medical_specialtyBrain DeathWaiting ListsContext (language use)030230 surgery03 medical and health sciencesLiver disease0302 clinical medicinemedicineLiving DonorsHumansIntensive care medicineCause of deathMachine perfusionHepatologybusiness.industryFatty liverGastroenterologyAge FactorsHepatitis Cmedicine.diseaseHepatitis CTissue DonorsLiver TransplantationTransplantationFatty LiverDonationKidney Failure Chronic030211 gastroenterology & hepatologybusinessThe lancet. Gastroenterologyhepatology
researchProduct

Special Considerations for Antihypertensive Agents in Dialysis Patients

2010

Hypertension is present in most patients with end-stage renal disease and likely contributes to the premature cardiovascular disease in dialysis patients. Previous practice guidelines have recommended that, in patients on chronic dialysis, blood pressure (BP) should be reduced below 130/80 mm Hg. This is based on opinions but not strong evidence, since no concrete information exists about which BP values should be the parameter to follow and which should be the target BP values. The majority of the antihypertensive agents can be used in this population, but the pharmacokinetics altered by the impaired kidney function and dialyzability influence the appropriate dosage as well as the time and…

medicine.medical_specialtyCardiotonic AgentsHypertension RenalCombination therapyMetabolic Clearance Ratemedicine.drug_classVasodilator Agentsmedicine.medical_treatmentAdrenergic beta-AntagonistsPopulationAngiotensin-Converting Enzyme InhibitorsCardiotonic AgentsRenal DialysisInternal medicinemedicineHumansDrug InteractionsDiureticseducationAntihypertensive drugAntihypertensive AgentsDialysisRandomized Controlled Trials as Topiceducation.field_of_studybusiness.industryHematologyGeneral MedicineCalcium Channel Blockersmedicine.diseaseEndocrinologyBlood pressureCardiovascular DiseasesNephrologyPractice Guidelines as TopicPolypharmacyKidney Failure ChronicDrug Therapy CombinationHemodialysisbusinessAngiotensin II Type 1 Receptor BlockersKidney diseaseBlood Purification
researchProduct

Enhanced prediction of hemoglobin concentration in a very large cohort of hemodialysis patients by means of deep recurrent neural networks.

2019

Erythropoiesis Stimulating Agents (ESAs) have become a standard anemia management tool for End Stage Renal Disease (ESRD) patients. However, dose optimization constitutes an extremely challenging task due to huge inter and intra-patient variability in the responses to ESA administration. Current data-based approaches to anemia control focus on learning accurate hemoglobin prediction models, which can be later utilized for testing competing treatment choices and choosing the optimal one. These methods, despite being proven effective in practice, present several shortcomings which this paper intends to tackle. Namely, they are limited to a small cohort of patients and, even then, they fail to…

medicine.medical_specialtyComputer scienceAnemiamedicine.medical_treatmentMedicine (miscellaneous)End stage renal diseaseTask (project management)03 medical and health sciencesHemoglobins0302 clinical medicineArtificial IntelligenceRenal DialysismedicineHumansProspective StudiesIntensive care medicine030304 developmental biology0303 health sciencesbusiness.industryDeep learningmedicine.diseaseRecurrent neural networkCohortHematinicsKidney Failure ChronicArtificial intelligenceHemodialysisNeural Networks Computerbusiness030217 neurology & neurosurgeryPredictive modellingArtificial intelligence in medicine
researchProduct